A detailed history of Alps Advisors Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 53,421 shares of ARVN stock, worth $1.02 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
53,421
Previous 53,365 0.1%
Holding current value
$1.02 Million
Previous $1.42 Million 7.39%
% of portfolio
0.01%
Previous 0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.66 - $32.73 $1,324 - $1,832
56 Added 0.1%
53,421 $1.32 Million
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $130,665 - $215,816
5,342 Added 11.12%
53,365 $1.42 Million
Q1 2024

May 14, 2024

BUY
$36.38 - $52.31 $459,333 - $660,466
12,626 Added 35.67%
48,023 $1.98 Million
Q4 2023

Feb 14, 2024

SELL
$14.19 - $42.33 $57,739 - $172,240
-4,069 Reduced 10.31%
35,397 $1.46 Million
Q3 2023

Nov 14, 2023

BUY
$19.64 - $28.21 $4,183 - $6,008
213 Added 0.54%
39,466 $775,000
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $90,309 - $130,623
4,156 Added 11.84%
39,253 $974,000
Q1 2023

May 10, 2023

SELL
$26.15 - $37.26 $25,757 - $36,701
-985 Reduced 2.73%
35,097 $958,000
Q4 2022

Feb 14, 2023

BUY
$32.47 - $57.24 $1.17 Million - $2.07 Million
36,082 New
36,082 $1.23 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.